TNFSF11 and plasma cell myeloma: A CD38 monoclonal antibody (daratumumab, used in a clinical trial to treat patients with multiple myeloma [45]) suppressed osteoclastogenesis and bone resorption induced by RANKL in monocytes derived from patients with multiple myeloma [46].